Supplemental material - van der Kolk et al., 2020
Description
Supplemental Material related to "Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial. T. Niemeyer - van der Kolk et al., 2020, Journal of the American Academy of Dermatology." Supplemental Material S1. Clinical study protocol. Supplemental Material S2. Microbiome report. Supplemental Material S3. Study flow chart. Supplemental Material S4. Staphylococcus abundance over time. A) Staphylococcus abundance over time of the target lesion in the omiganan 1% treatment group, B) Staphylococcus abundance of the target lesion over time in the omiganan 1.75% treatment group, C) Staphylococcus abundance of the target lesion over time in the omiganan 2.5% treatment group, D) Staphylococcus abundance of the target lesion over time in the vehicle treatment group, E) Summary of the change in Staphylococcus abundance of the target lesion, boxplots and median (blue text), and F). Supplemental Material S5. Transepidermal water loss. A) Transepidermal water loss lesional vs. non-lesional skin, B) mRNA expression of IL-13 relative to GAPDH lesional vs. non-lesional skin, C) mRNA expression of eotaxin relative to GAPDH lesional vs. non-lesional skin, D) mRNA expression of IL-31 relative to GAPDH lesional vs. non-lesional skin.